十肽-12治疗黄褐斑临床疗效观察  

Clinical efficacy and safety of decapeptide-12 in the treatment of melasma

作　　者：刘丽红[1] 樊昕[1] 安俞熙[1] 徐阳[1] 杨蓉娅[1] 

机构地区：[1]北京军区总医院全军皮肤损伤修复研究所激光美容中心,北京100700

出　　处：《实用皮肤病学杂志》2015年第4期263-265,共3页Journal of Practical Dermatology

摘　　要：目的：观察露明斯 TM（十肽-12）治疗黄褐斑的安全性及有效性。方法选取30例黄褐斑受试者，以治疗前为基线，通过治疗前后进行自身对照。每日使用露明斯 TM亮白组合于面部，共使用6～8周。分别于治疗前、治疗后1个月、3个月拍摄VISIA图像观察疗效，并由临床医生根据患者黄褐斑面积及颜色进行4级评分，计算总积分及积分下降指数；由受试者对疗效进行满意度评价，共随访6个月。结果治疗3个月，与治疗前相比，色斑痊愈5例，治愈率为16.7%；显效14例（46.7%）；好转7例（23.3%）；无效4例（13.3%），总有效率为86.7%。随访6个月，5例（16.7%）患者轻度复发。治疗结束后60%以上的受试者表示对治疗满意或非常满意。未见明显不良反应。结论露明斯 TM治疗中国人面部黄褐斑效果较好、安全性高。Objective To investigate the efifcacy and safety of lumixylTM （decapeptide-12） for melasma therapy. Methods Total 30 volunteers with melasma were enrolled in this study by self-control before and after the treatment. Subjects received a total of lumixylTM daily for 6 to 8 weeks, and then the efifcacy at 1 month and 3 months after the treatment were evaluated by digital photography and VISIA by both the doctors and volunteers, followed up for 6 months. Results From the baseline to to 3 months after of treatment, 5 case recovered （16.7%）, signiifcant improvement 14 case （46.7%）, slight improvement 7 case （23.3%）, no change 4 case （13.3%）. The total efifciency was 86.7%. There was a signiifcant statistical difference between before and after the treatment （P〈0.05）. Follow-up 6 months, 5 cases （16.7%） had mild relapse. Over 60%subjects considered satisfactory or very satisfactory after the course of treatment. No signiifcant adverse reactions occurred. Conclusion LumixylTM is safe and effective in the treatment of melasma in Chinese.

关 键 词：黄褐斑 临床疗效 

分 类 号：R758.42[医药卫生—皮肤病学与性病学]